Acepodia, Inc.
Acepodia, Inc. operates as a clinical stage biotechnology company. The company engages in developing cell therapies with its antibody cell conjugation (ACC) platform technology to address cancer care. It develops AD2C targeting GPC3 for HCC which is in preclinical stage; ACE 1831 targeting CD20 that is in phase 1 clinical trial; ACE 2016 targeting EGFR, which is in Phase 1 clinical trial; ACE183 … Read more
Acepodia, Inc. (6976) - Total Assets
Latest total assets as of June 2024: NT$6.99 Billion TWD
Based on the latest financial reports, Acepodia, Inc. (6976) holds total assets worth NT$6.99 Billion TWD as of June 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Acepodia, Inc. - Total Assets Trend (2020–2023)
This chart illustrates how Acepodia, Inc.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Acepodia, Inc. - Asset Composition Analysis
Current Asset Composition (December 2023)
Acepodia, Inc.'s total assets of NT$6.99 Billion consist of 93.0% current assets and 7.1% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 92.3% |
| Accounts Receivable | NT$0.00 | 0.0% |
| Inventory | NT$0.00 | 0.0% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$0.00 | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2020–2023)
This chart illustrates how Acepodia, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Acepodia, Inc.'s current assets represent 93.0% of total assets in 2023, an increase from 91.4% in 2020.
- Cash Position: Cash and equivalents constituted 92.3% of total assets in 2023, up from 89.1% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Acepodia, Inc. Competitors by Total Assets
Key competitors of Acepodia, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Acepodia, Inc. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Acepodia, Inc. generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Acepodia, Inc. is currently not profitable relative to its asset base.
Acepodia, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 60.01 | 75.08 | 30.08 |
| Quick Ratio | 60.01 | 75.08 | 30.08 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$6.28 Billion | NT$ 6.57 Billion | NT$ 3.66 Billion |
Acepodia, Inc. - Advanced Valuation Insights
This section examines the relationship between Acepodia, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.46 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | 76.1% |
| Total Assets | NT$6.82 Billion |
| Market Capitalization | $127.76 Million USD |
Valuation Analysis
Below Book Valuation: The market values Acepodia, Inc.'s assets below their book value (0.02 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Acepodia, Inc.'s assets grew by 76.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Acepodia, Inc. (2020–2023)
The table below shows the annual total assets of Acepodia, Inc. from 2020 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | NT$6.82 Billion | +76.07% |
| 2022-12-31 | NT$3.87 Billion | -0.60% |
| 2021-12-31 | NT$3.90 Billion | +1438.41% |
| 2020-12-31 | NT$253.24 Million | -- |